Lipoprotein(a) Testing for Cardiovascular Risk Assessment and Use of Lipid-Lowering Therapy in a Large Midwest Cohort
Although testing for Lp(a) has improved, there is room for significant improvement, particularly in those with ASCVD. The higher use of LLT in all risk categories indicate that Lp(a) testing may have influenced treatment decisions.
Authors
- Elizabeth Tuohy
- Otto A. Sánchez (ORCID: https://orcid.org/0000-0003-0256-8065)
- Michael D. Miedema (ORCID: https://orcid.org/0000-0003-0499-5810)
- F Martignoni (ORCID: https://orcid.org/0009-0005-9370-8722)
- Thomas Knickelbine (ORCID: https://orcid.org/0000-0001-5628-3722)
- Ellen Cravero (ORCID: https://orcid.org/0009-0000-3035-3825)
Institutions
- Texas Tech University (US)
- Minneapolis Heart Institute Foundation (US)
- Texas Tech University Health Sciences Center (US)
Publication Details
- Journal
- American Journal of Preventive Cardiology
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1016/j.ajpc.2025.101267
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Minneapolis Heart Institute Foundation